IDEXX Laboratories, Inc. $IDXX Shares Bought by OMERS ADMINISTRATION Corp

Key Points

• OMERS Administration increased its IDEXX Laboratories stake by 88.2% during the first quarter, purchasing 5,628 additional shares and bringing its total to 12,011 shares valued at approximately $6.75 million.
• Institutional investors hold 87.84% of IDEXX’s outstanding stock, with State Street, J. Stern & Co., Geode Capital Management and Invesco among major holders that also increased positions.
• IDEXX exceeded quarterly expectations with $3.47 in EPS and $1.14 billion in revenue, while revenue grew 14.3% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $751, despite recent target reductions.

OMERS ADMINISTRATION Corp grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 88.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,011 shares of the company's stock after purchasing an additional 5,628 shares during the period. OMERS ADMINISTRATION Corp's holdings in IDEXX Laboratories were worth $6,749,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in IDXX. Elyxium Wealth LLC purchased a new position in IDEXX Laboratories in the 4th quarter valued at approximately $3,666,459,000. State Street Corp increased its holdings in shares of IDEXX Laboratories by 4.0% in the 4th quarter. State Street Corp now owns 3,656,626 shares of the company's stock valued at $2,473,817,000 after acquiring an additional 138,956 shares during the last quarter. J. Stern & Co. LLP raised its position in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after acquiring an additional 2,642,200 shares in the last quarter. Geode Capital Management LLC lifted its stake in IDEXX Laboratories by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company's stock worth $1,749,380,000 after purchasing an additional 86,263 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of IDEXX Laboratories by 13.8% in the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company's stock valued at $1,016,296,000 after buying an additional 181,955 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDXX opened at $544.32 on Monday. IDEXX Laboratories, Inc. has a 52-week low of $518.55 and a 52-week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $42.94 billion, a P/E ratio of 40.08, a P/E/G ratio of 2.98 and a beta of 1.55. The firm's 50 day moving average is $556.27 and its 200-day moving average is $594.80.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analysts' expectations of $1.12 billion. During the same period in the prior year, the business posted $2.91 EPS. The business's revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Weiss Ratings cut shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a report on Tuesday, July 14th. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 price target for the company. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a research note on Tuesday, March 31st. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Finally, UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.